Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 2 study of zelenectide pevedotin in previously treated NECTIN4-amplified advanced or metastatic non-small cell lung cancer
2025-521115-40-00Phase 2Authorised
- Sponsor
- Bicycle Therapeutics
- Start
- Sep 2025
- Modality
- Cytotoxic ADCs → Antibody-Drug Conjugates (ADCs) → Antibody Conjugates → Antibody-Based Therapeutics, Peptide-Drug Conjugates → Peptide Conjugates → Peptides, Cyclic Peptides → Modified Peptides → Peptides
- Countries
- 6
01
Overview
Phase 2, open-label trial of zelenectide pevedotin in non-small cell lung cancer (NSCLC) (2 cohorts), sponsored by Bicycle Therapeutics. Primary endpoint: Objective response rate. Planned start Sep 2025; status: authorised.
02
Drugs
zelenectide pevedotin
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on 2025-521115-40-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2025-521115-40-00.